Clinical Relevance of ATRX/DAXX Gene Mutations and ALT in Functioning Pancreatic Neuroendocrine Tumors.

IF 11.3 2区 医学 Q1 ENDOCRINOLOGY & METABOLISM Endocrine Pathology Pub Date : 2025-02-15 DOI:10.1007/s12022-025-09848-1
Brenna R van T Veld, Wenzel M Hackeng, Claudio Luchini, Lodewijk A A Brosens, Koen M A Dreijerink
{"title":"Clinical Relevance of ATRX/DAXX Gene Mutations and ALT in Functioning Pancreatic Neuroendocrine Tumors.","authors":"Brenna R van T Veld, Wenzel M Hackeng, Claudio Luchini, Lodewijk A A Brosens, Koen M A Dreijerink","doi":"10.1007/s12022-025-09848-1","DOIUrl":null,"url":null,"abstract":"<p><p>Functioning pancreatic neuroendocrine tumors (PanNETs) represent a subset of PanNETs that cause symptoms due to hormonal activity. Insulinoma is the most common functioning PanNET type. Mutations in the alpha thalassemia/mental retardation X-linked (ATRX) and death domain-associated protein (DAXX) genes result in genomic instability. ATRX/DAXX mutations and associated alternative lengthening of telomeres (ALT) are common in non-functioning PanNETs and associated with aggressive tumor behavior. Recent reports have shown that ATRX/DAXX mutations and ALT are also present in functioning PanNETs. In this review, we summarize the literature addressing ATRX/DAXX mutations and ALT in functioning PanNETs and discuss the clinical relevance with regard to distinguishing aggressive and indolent functioning tumors. ATRX/DAXX gene mutations and/or ALT have been reported in insulinoma, glucagonoma, gastrinoma, VIPoma and calcitoninoma. In insulinoma, the presence of ATRX/DAXX mutations and ALT are associated with aggressive behavior and could therefore be used as prognostic biomarkers. Although ATRX/DAXX mutation and ALT assessment may currently not be the standard of care in routine diagnostic pathology practice, the use of DAXX/ATRX immunohistochemistry at least can be encouraged not only for non-functioning but also for functioning PanNETs.</p>","PeriodicalId":55167,"journal":{"name":"Endocrine Pathology","volume":"36 1","pages":"3"},"PeriodicalIF":11.3000,"publicationDate":"2025-02-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11829919/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Endocrine Pathology","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1007/s12022-025-09848-1","RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"ENDOCRINOLOGY & METABOLISM","Score":null,"Total":0}
引用次数: 0

Abstract

Functioning pancreatic neuroendocrine tumors (PanNETs) represent a subset of PanNETs that cause symptoms due to hormonal activity. Insulinoma is the most common functioning PanNET type. Mutations in the alpha thalassemia/mental retardation X-linked (ATRX) and death domain-associated protein (DAXX) genes result in genomic instability. ATRX/DAXX mutations and associated alternative lengthening of telomeres (ALT) are common in non-functioning PanNETs and associated with aggressive tumor behavior. Recent reports have shown that ATRX/DAXX mutations and ALT are also present in functioning PanNETs. In this review, we summarize the literature addressing ATRX/DAXX mutations and ALT in functioning PanNETs and discuss the clinical relevance with regard to distinguishing aggressive and indolent functioning tumors. ATRX/DAXX gene mutations and/or ALT have been reported in insulinoma, glucagonoma, gastrinoma, VIPoma and calcitoninoma. In insulinoma, the presence of ATRX/DAXX mutations and ALT are associated with aggressive behavior and could therefore be used as prognostic biomarkers. Although ATRX/DAXX mutation and ALT assessment may currently not be the standard of care in routine diagnostic pathology practice, the use of DAXX/ATRX immunohistochemistry at least can be encouraged not only for non-functioning but also for functioning PanNETs.

查看原文
分享 分享
微信好友 朋友圈 QQ好友 复制链接
本刊更多论文
功能性胰腺神经内分泌肿瘤中 ATRX/DAXX 基因突变和 ALT 的临床意义
功能性胰腺神经内分泌肿瘤(PanNET)是由于激素活动而导致症状的 PanNET 的一个分支。胰岛素瘤是最常见的功能性 PanNET 类型。阿尔法地中海贫血/智力迟钝X连锁(ATRX)和死亡结构域相关蛋白(DAXX)基因突变会导致基因组不稳定。ATRX/DAXX突变和相关的端粒替代性延长(ALT)在无功能的PanNET中很常见,并与侵袭性肿瘤行为有关。最近的报告显示,ATRX/DAXX突变和ALT也存在于功能正常的PanNET中。在这篇综述中,我们总结了有关功能性 PanNET 中 ATRX/DAXX 基因突变和 ALT 的文献,并讨论了其与区分侵袭性和非侵袭性功能性肿瘤的临床相关性。胰岛素瘤、胰高血糖素瘤、胃泌素瘤、VIP 瘤和降钙素瘤中都有 ATRX/DAXX 基因突变和/或 ALT 的报道。在胰岛素瘤中,ATRX/DAXX 突变和 ALT 的存在与侵袭行为有关,因此可用作预后生物标志物。虽然 ATRX/DAXX 突变和 ALT 评估目前可能还不是常规病理诊断实践中的标准,但至少可以鼓励使用 DAXX/ATRX 免疫组化,不仅适用于无功能的 PanNET,也适用于有功能的 PanNET。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 去求助
来源期刊
Endocrine Pathology
Endocrine Pathology 医学-病理学
CiteScore
12.30
自引率
20.50%
发文量
41
审稿时长
>12 weeks
期刊介绍: Endocrine Pathology publishes original articles on clinical and basic aspects of endocrine disorders. Work with animals or in vitro techniques is acceptable if it is relevant to human normal or abnormal endocrinology. Manuscripts will be considered for publication in the form of original articles, case reports, clinical case presentations, reviews, and descriptions of techniques. Submission of a paper implies that it reports unpublished work, except in abstract form, and is not being submitted simultaneously to another publication. Accepted manuscripts become the sole property of Endocrine Pathology and may not be published elsewhere without written consent from the publisher. All articles are subject to review by experienced referees. The Editors and Editorial Board judge manuscripts suitable for publication, and decisions by the Editors are final.
期刊最新文献
Clinical Relevance of ATRX/DAXX Gene Mutations and ALT in Functioning Pancreatic Neuroendocrine Tumors. Deep Learning Enabled Scoring of Pancreatic Neuroendocrine Tumors Based on Cancer Infiltration Patterns. Evaluating CK20 and MCPyV Antibody Clones in Diagnosing Merkel Cell Carcinoma. Glucagon-Producing Pancreatic Neuroendocrine Tumors (Glucagonomas) are Enriched in Aggressive Neoplasms with ARX and PDX1 Co-expression, DAXX/ATRX Mutations, and ALT (Alternative Lengthening of Telomeres). Catching the Silent Culprits: TERT Promoter Mutation Screening of Minimally Invasive Follicular and Oncocytic Thyroid Carcinoma in Clinical Practice.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
已复制链接
已复制链接
快去分享给好友吧!
我知道了
×
扫码分享
扫码分享
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1